A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2012
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 29 Jul 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 20 Jan 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.